Combination of endostatin and a protein kinase Cα DNA enzyme improves the survival of rats with malignant glioma

Neoplasia

Volumn 4, Issue 6, 2002, Pages 474-479

  Sorensen, Dag R ^a   Leirdal, Marianne ^b   Iversen, Per Ole ^a   Sioud, Mouldy ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b Radium Hospital   (Norway)

Author keywords

Angiogenesis; DNA enzyme; Endostatin; Gliosarcoma; Protein kinase C

Indexed keywords

ENDOSTATIN; PROTEIN KINASE C ALPHA; ANGIOGENESIS INHIBITOR; COLLAGEN; MESSENGER RNA; PEPTIDE FRAGMENT; PROTEIN KINASE C; RIBOZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMAN; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; STEREOTAXIC SURGERY; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR CELL LINE; ANIMAL; APOPTOSIS; BRAIN TUMOR; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FEMALE; GENETICS; GLIOSARCOMA; IN VITRO STUDY; MALE; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; PATHOLOGY; SARCOMA; SURVIVAL RATE; VASCULARIZATION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIVISION; COLLAGEN; DRUG THERAPY, COMBINATION; ENDOSTATINS; FEMALE; GLIOSARCOMA; IN SITU NICK-END LABELING; MALE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; RATS; RNA, CATALYTIC; RNA, MESSENGER; SARCOMA, EXPERIMENTAL; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0036858411     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900271     Document Type: Article

References (38)

1. Kleihues P, and Cavenee WK (1997). Pathology and Genetics of Tumours of the Nervous System. International Agency for Research on Cancer, Lyon, France.
2. Hanahan D, and Weinberg RA (2000). The hallmarks of cancer. Cell 100, 57-70.
3. Plattner R, Gupta S, Khosravi-Far R, Sato KY, Perucho M, Der CJ, and Stanbridge EJ (1999). Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene 18, 1807-17.
4. Silvany RE, Eliazer S, Wolff NC, and Ilaria RL Jr (2000). Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 19, 4523-30.
5. Reed JC (1998). Bcl-2 family proteins. Oncogene 17, 3225-36.
6. Zamzami N, Brenner C, Marzo I, Susin SA, and Kroemer G (1998). Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16, 2265-82.
7. Masur K, Lang K. Niggemann B, Zanker KS, and Entschladen F (2001). High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell 12, 1973-82.
8. Couldwell WT, Antel JP, Apuzzo ML, and Yong VW (1990). Inhibition of growth of established human glioma cell lines by modulators of the protein kinase-C system. J Neurosurg 73, 594-600.
9. Sioud M, and Sorensen DR (1998). A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth. Nat Biotechnol 16, 556-61.
10. Newton AC, and Johnson JE (1998). Protein kinase C: A paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta 1376, 155-72.
11. Dekker LV, and Parker PJ (1994). Protein kinase C - A question of specificity. Trends Biochem Sci 19, 73-77.
12. Sioud M, and Leirdal M (2000). Design of nuclease resistant protein kinase calpha DNA enzymes with potential therapeutic application. J Mol Biol 296, 937-47.
13. Haseloff J, and Gerlach WL (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585-91.
14. Santoro SW, and Joyce GF (1997). A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 94, 4262-66.
15. Leirdal M, and Sioud M (1999). Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells. Br J Cancer 80, 1558-64.
16. O'Brian C, Vogel VG, Singletary SE, and Ward NE (1989). Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49, 3215-17.
17. Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, and Parker PJ (1995). MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 95, 1906-15.
18. Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82, 4-6.
19. Vajkoczy P, Schilling L, Ullrich A, Schmiedek P, and Menger MD (1998). Characterization of angiogenesis and microcirculation of high-grade glioma: An intravital multifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab 18, 510-20.
20. Johansson M, Bergenheim AT, Widmark A, and Henriksson R (1999). Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. Br J Cancer 80, 142-48.
21. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, and Min W (1999). Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 17. 343-48.
22. Hanahan D, and Folkman J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-64.
23. Beck L Jr, and D'Amore PA (1997). Vascular development: Cellular and molecular regulation. FASEB J 11, 365-73.
24. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-85.
25. Boehm T, Folkman J, Browder T, and O'Reilly MS (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
26. Sorensen D, Read T-A, Porwol T, Olsen BR, Timpl R, Sasaki T, Iversen PO, Benestad HB, Sim BKL, and Bjerkvig R (2002). Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma. Neuro-Oncol 4, 1-8.
27. Sioud M (2001). Nucleic acid enzymes as a novel generation of antigene agents. Curr Mol Med 1, 575-88.
28. Sim BKL, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, O'Reilly M, Tomaszewski E, and Fortier AH (1999). Zinc ligand-disrupted recombinant human endostatin: Potent inhibitor of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3, 41-51.
29. Mella O, Bjerkvig R, Schem BC, Dahl O, and Laerum OD (1990). A cerebral glioma model for experimental therapy and in vivo invasion studies in syngeneic BD IX rats. J Neurooncol 9, 93-104.
30. Rehbinder C, Baneux P, Forbes D, van Herck H, Nicklas W, Rugaya Z, and Winkler G (1996). FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea pig and rabbit experimental units. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health accepted by the FELASA Board of Management, November 1995. Lab Anim 30, 193-208.
31. DeAngelis LM (2001). Brain tumors. N Engl J Med 344, 114-23.
32. Ruvolo PP, Deng X, Carr BK, and May WS (1998). A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 273, 25436-42.
33. Couldwell WT, Uhm JH, Antel JP, and Yong VW (1991). Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 29, 880-86; discussion 886-87.
34. Whelan RD, and Parker PJ (1998). Loss of protein kinase C function induces an apoptotic response. Oncogene 16, 1939-44.
35. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, and Kwon YG (2000). Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60, 5410-13.
36. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR, Hjelstuen MH, Haraldseth O, and Bjerkvig R (2001). Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 19, 29-34.
37. Leirdal M, and Sioud M (2000). Protein kinase C alpha isoform regulates the activation of the MAP kinase ERK1/2 in human glioma cells: Involvement in cell survival and gene expression. Mol Cell Biol Res Commun 4, 106-10.
38. Ding I, Sun JZ, Fenton B, Liu WM, Kimsely P, Okunieff P, and Min W (2001). Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res 61, 526-31.